Comparison of radiomics prediction models for lung metastases according to four semiautomatic segmentation methods in soft-tissue sarcomas of the extremities

2022 ◽  
Author(s):  
Heesoon Sheen ◽  
Han-Back Shin ◽  
Jung Young Kim
Keyword(s):  
Soft Tissue ◽  
Prediction Models ◽  
Lung Metastases ◽  
Soft Tissue Sarcomas ◽  
Semiautomatic Segmentation ◽  
Segmentation Methods

scholarly journals Manual versus semiautomatic segmentation of soft-tissue sarcomas on magnetic resonance imaging: evaluation of similarity and comparison of segmentation times

2021 ◽  
Vol 54 (3) ◽  
pp. 155-164
Author(s):  
Fernando Carrasco Ferreira Dionisio ◽  
Larissa Santos Oliveira ◽  
Mateus de Andrade Hernandes ◽  
Edgard Eduard Engel ◽  
Paulo Mazzoncini de Azevedo-Marques ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Dice Similarity Coefficient ◽  
Intraobserver Variability ◽  
Resonance Imaging ◽  
Semiautomatic Segmentation ◽  
Significant Difference ◽  
Degree Of Similarity

Abstract Objective: To evaluate the degree of similarity between manual and semiautomatic segmentation of soft-tissue sarcomas on magnetic resonance imaging (MRI). Materials and Methods: This was a retrospective study of 15 MRI examinations of patients with histopathologically confirmed soft-tissue sarcomas acquired before therapeutic intervention. Manual and semiautomatic segmentations were performed by three radiologists, working independently, using the software 3D Slicer. The Dice similarity coefficient (DSC) and the Hausdorff distance were calculated in order to evaluate the similarity between manual and semiautomatic segmentation. To compare the two modalities in terms of the tumor volumes obtained, we also calculated descriptive statistics and intraclass correlation coefficients (ICCs). Results: In the comparison between manual and semiautomatic segmentation, the DSC values ranged from 0.871 to 0.973. The comparison of the volumes segmented by the two modalities resulted in ICCs between 0.9927 and 0.9990. The DSC values ranged from 0.849 to 0.979 for intraobserver variability and from 0.741 to 0.972 for interobserver variability. There was no significant difference between the semiautomatic and manual modalities in terms of the segmentation times (p > 0.05). Conclusion: There appears to be a high degree of similarity between manual and semiautomatic segmentation, with no significant difference between the two modalities in terms of the time required for segmentation.

3417 Stereotactic radiotherapy in the treatment of lung metastases from bone and soft tissue sarcomas: Final results

2015 ◽  
Vol 51 ◽  
pp. S694
Author(s):  
F. Salvi ◽  
R. Frakulli ◽  
A. Longhi ◽  
S. Ferrari ◽  
S. Cammelli ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Stereotactic Radiotherapy ◽  
Lung Metastases ◽  
Soft Tissue Sarcomas

scholarly journals Myxoid Malignant Fibrous Histiocytoma with Multiple Primary Sites

Sarcoma ◽  
2002 ◽  
Vol 6 (1) ◽  
pp. 51-55 ◽  
Author(s):  
Jeffrey H. Muler ◽  
Augusto F. Paulino ◽  
Diane Roulston ◽  
Laurence H. Baker
Keyword(s):  
Soft Tissue ◽  
Malignant Fibrous Histiocytoma ◽  
Lung Metastases ◽  
Fibrous Histiocytoma ◽  
Soft Tissue Sarcomas ◽  
Distant Metastases ◽  
Common Site ◽  
Common Location ◽  
Multiple Primary ◽  
Multiple Primary Sites

Malignant fibrous histiocytoma (MFH) is one of the most common types of soft tissue sarcomas in adults. The most common location of MFH are the extremities and the trunk, with the most common site for distant metastases being the lung. We describe a case with multiple synchronous sites of myxoid MFH but no lung metastases and presence of abnormalities of 19p13.

Surgical and non-surgical treatment of pulmonary metastases of soft tissue sarcomas

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 9582-9582
Author(s):  
J. P. Sade ◽  
M. Chacon ◽  
J. M. O′Connor ◽  
C. Pupareli ◽  
M. Varela ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Soft Tissue ◽  
Pulmonary Metastases ◽  
Lung Metastases ◽  
Univariate Analysis ◽  
Soft Tissue Sarcomas ◽  
Group A ◽  
Group B ◽  
The Impact ◽  
Non Surgical Treatment

9582 Background: Several reports have shown a prolonged survival after surgery for lung metastases from soft tissue sarcomas (STS). This finding is in contrast with the results from chemotherapy. We performed a retrospective analysis to determine the impact of surgical and non surgical treatment in terms of time to progression (TTP) and disease specific survival (DSS). Methods: A review of 144 patients (pts) with STS treated at a single institution (december 1994-february 2005) was performed. Median age: 45 years old, female 53%. Extremity was the primary site in 54 pts and leiomyosarcoma was the most common histologic type (24%). In 42 pts pulmonary metastases were synchronous. The median disease free interval (DFI) was 11 months. Surgical treatment on the lung lesions was performed in 48 pts (group A), while 96 received medical treatment (group B). Results: Surgery was R0 in 90% of group A pts with only 4 lobectomies and 36 metastasectomies. Nine pts (19%) in this group received neo or adyuvant chemotherapy. The median TTP was 11 months (2–107) and 21 pts (44%) relapse in the lung (8 lung + other site). At the time of this analysis 13 pts (27%) are NED, with a DSS of 24 months for the surgical group. 28% remain alive at 5 years. In a univariate analysis only the number of lung metastases (1 vs 2 or more) was significant for DSS (p=0.05). Group B was treated primarily with chemotherapy being doxorubicin the most common drug used (89%). The RR was 23% with a median TTP of 3 months and a DSS of 12 months (1–98). Conclusions: The present results are similar with previous reports in terms of overall survival. Paliative chemotherapy showed modest activity and surgical treatment remains the only curative treatment modality for pts with lung metastases from STS. No significant financial relationships to disclose.

A retrospective study of parameters influencing survival after surgical resection of lung metastases of bone and soft tissue sarcomas

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 10541-10541
Author(s):  
S. Piperno-Neumann ◽  
K. Homicsko ◽  
S. Mussot ◽  
P. Anract ◽  
V. Laurence ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Retrospective Study ◽  
Soft Tissue ◽  
Lung Metastases ◽  
Univariate Analysis ◽  
Tumor Biology ◽  
Surrogate Marker ◽  
Soft Tissue Sarcomas ◽  
High Grade ◽  
Isolated Lung

10541 Background: Due to the high rate of isolated lung metastases of sarcomas, a multidisciplinary approach combining chemotherapy with pulmonary metastasectomy (PM) is helpful to achieve R0 resection and try to increase progression free survival (PFS) and overall survival (OS). The aim of this retrospective study is to describe the clinical and tumor features of 70 consecutive operated patients and to identify the factors influencing survival. Methods: 70 patients undergoing PM at Foch Hospital or CCML between 1995 and 2006 were identified, with follow-up (FU) for a minimum of 3 years after last PM. Statview program has been used to create survival curves, Cox proportional hazard model for multivariate analysis. Results: 64 patients had grade II/III sarcomas of mainly lower limb origin.15 patients had synchronous lung metastases, 35 showed bilateral lesions (mean number of 4, mean size of 12 mm). No patient had extrapulmonary disease at the time of PM. 51% were primary bone sarcomas (24 osteo, 9 Ewing, 3 chondro) and 49 % were soft tissue sarcomas (including 12 synovial, 9 leio). The primary tumor treatment consisted in conservative surgery in 58 patients (83%). 49 patients received neo and/or adjuvant chemotherapy, 22 patients had postoperative radiotherapy. All patients underwent PM: 1 pneumonectomy, 15 lobectomy and 54 wedge resection. 21 patients required bilateral PM. The resection margins were classified R0/R1/R2 in 54/16/0 patients, R0 was confirmed in 44 by CT scan in a month after PM. With a median FU from diagnosis of 7.7 years, the median OS for all patients reached 59 months, and the median survival after metastasectomy (OSPM) 31 months. The 5-year OS and OSPM rates were 77% and 59% respectively. The mean PFS was 20 months. 25 patients underwent subsequent PM for recurrent lung metastases, 30 are still alive. On univariate analysis, primary high grade, DFI>24 months, number of metastases>3 and largest diameter>25 mm were significant negative factors for OS. Multivariate analysis confirmed the importance of high grade, DFI, and size of metastases for OS. R0 was associated with prolonged PFS after PM. Conclusions: Accurate patient selection and technical aspects of PM are related to optimal R0 rate. DFI may be a surrogate marker for tumor biology. No significant financial relationships to disclose.

scholarly journals Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin

Cancers ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 432 ◽  
Author(s):  
Alexandre de Nonneville ◽  
Dominique Barbolosi ◽  
Maeva Andriantsoa ◽  
Raouf El-Cheikh ◽  
Florence Duffaud ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neutrophil Count ◽  
Predictive Factor ◽  
Lung Metastases ◽  
Performance Status ◽  
Survival Rates ◽  
Soft Tissue Sarcomas ◽  
Progression Free Survival ◽  
Tumor Grade ◽  
Free Survival

Introduction: Based on a mathematical model of trabectedin-induced neutropenia, we assessed the predictive value of absolute neutrophil count (ANC) on progression-free survival (PFS) in an independent validation cohort of patients treated with trabectedin. Methods: We collected data from 87 patients in two expert centers who received at least two cycles of trabectedin for soft tissue sarcomas (STS) treatment. Correlations between ANC, patients’ characteristics, and survival were assessed, and a multivariate model including tumor grade, performance status, ANC, and hemoglobin level was developed. Results: Therapeutic ANC ≥ 7.5 G/L level was associated with shorter PFS: 3.22 months (95% confidence interval (CI), 1.57–4.87) in patients with ANC ≥ 7.5 G/L vs. 5.78 months (95% CI, 3.95–7.61) in patients with ANC < 7.5 G/L (p = 0.009). Age, primary localization, lung metastases, dose reduction, hemoglobin, and albumin rates were also associated with PFS. In multivariate analysis, ANC ≥ 7.5 G/L was independently associated with poor PFS and overall survival. Conclusion: We validated increased pre-therapeutic ANC as a predictive factor of short PFS in patients starting trabectedin for STS. ANC appears to have an impact on survival rates and may be used as a decision-making tool for personalizing second-line strategies in patients with metastatic STS.

FDG-PET for the prediction of therapy outcome in patients with high risk soft tissue sarcomas receiving high dose chemotherapy with stem cell rescue

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 9562-9562
Author(s):  
P. Wuchter ◽  
B. Kasper ◽  
A. Dimitrakopoulou-Strauss ◽  
G. Egerer ◽  
U. Haberkorn ◽  
...  
Keyword(s):  
Stem Cell ◽  
Discriminant Analysis ◽  
High Risk ◽  
Soft Tissue ◽  
Fdg Pet ◽  
Lung Metastases ◽  
Soft Tissue Sarcomas ◽  
Vessel Density ◽  
Therapy Outcome ◽  
High Dose

9562 Background: Dynamic 2-deoxy-2-[18F]fluoro-D-glucose (FDG) PET studies were used to evaluate the FDG kinetics in pts.with high risk soft tissue sarcomas receiving induction chemotherapy consisting of adriamycin and ifosfamide (AI-G) prior to peripheral blood stem cell transplantation. The treatment effect was assessed regarding prediction of therapy outcome. Methods: The ongoing evaluation includes 8 pts. with 17 lesions. 7/8 pts. were classified as grade III with lung or multiple metastases. The restaging data served as reference for the PET data. All pts. were examined initially and after the first cycle of AI-G . The dynamic series were performed over the area of the primary tumor (n=5) or the lung metastases (n=3). SUV, fractal dimension (FD), k1, k2, k3, k4 and the vessel density (VB) were retrieved from the dynamic PET studies. Furthermore, FDG influx was calculated using the rates of the two compartment model and the formula (k1 × k3)/(k2 + k3). Discriminant analysis was applied for data analysis. Results: According to RECIST criteria, 3 pts. showed progressive disease (PD), one pt.stable disease (SD), one pt. no evidence of disease (NED) and two pts. partial remission (PR). Due to the small number of pts., we dichotomized the data in pts. with NED/PR (n=3) and pts. with SD/PD (n=4). Median SUV prior therapy was 8.3 in comparison to 4.3 after one cycle AI-G. Discriminant analysis using only the data of the initial FDG study and a single parameter for input demonstrated the highest correct classification rate (CCR) for VB (73%). The CCR of k1, k2, influx and FD were lower and equal (67%). The SUV of the first study demonstrated a lower CCR of 60%. Using the kinetic data only of the second study, CCR was equal for SUV, influx and FD as single input parameters (70%). Best results were obtained for the combination of VB of the first study and either influx or FD of the second study with a CCR of 89%. Conclusions: The significance of vessel density calculated from the data of the initial PET study and the non-significance for the second PET examination indicated a major change in the angiogenesis within the initial phase of treatment. On the basis of these data prediction of chemo-sensitivity of the tumor and moreover of the therapy outcome might be possible. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document